**ABSTRACT**

**Objective:** Diabetes mellitus is a major risk factor for cardiovascular disease (CVD). We investigated the relationship among biochemical and cardiac risk parameters with the methylenetetrahydrofolate reductase (MTHFR) C677T genotype in type 2 diabetes mellitus (T2DM) patients.

**Methods:** One hundred seven T2DM subjects with severe CVD diagnosed by angiography were included consecutively in this cross-sectional study. Biochemical and clinical parameters were obtained from patients who were not positive for nephropathy and retinopathy. MTHFR C677T genotypes were analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods. Normally and abnormally distributed continuous variables were analyzed using student t- and Mann-Whitney U tests. Categorical variables were analyzed using chi-square test.

**Results:** In the study, 31 T2DM subjects had the CC (29.0%), 62 had the CT (57.9%), and 14 had the TT (13.1%) genotypes. There were no significant differences between subjects with wild-type (677CC) and with mutant (677CT+677TT) alleles in terms of diabetes duration, visceral fat area, total cholesterol, triglyceride, fasting plasma glucose, systolic blood pressure, diastolic blood pressure, high-sensitivity C-reactive protein, homocysteine (Hcy), and carotid intima-media thickness values.

**Conclusion:** This study suggests that MTHFR gene polymorphisms can not be used as a marker for the assessment of cardiovascular risk in T2DM patients.

**Keywords:** type 2 diabetes mellitus, MTHFR C677T gene polymorphism, carotid intima-media thickness

**Introduction**

Noninsulin-dependent diabetes mellitus (NIDDM), also known as type 2 diabetes mellitus (T2DM), is a polygenic and multifactorial disease that is considered a major life-threatening health problem throughout the world (1). Diabetes mellitus is a major risk factor for cardiovascular disease and is associated with a high incidence of vascular complications (2). There may also be an interrelationship between factors, like endothelial dysfunction, dyslipidemia, platelet hyperaggregability, impaired hemostasis, and the development of vascular damage (3).

Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the transmethylation pathway, where homocysteine (Hcy) is converted to methionine. A common cytosine-to-thymidine substitution in the MTHFR gene at nucleotide 677 (C677T) changes a highly conserved alanine into valine, resulting in impaired enzymatic activity and leading to hyperhomocysteinemia, an independent risk factor for thrombotic disorders (4). The mutation was reported to be linked to moderate hyperhomocysteinemia in cases where homozygote (677TT) folate levels were low in comparison with heterozygotes or non-carriers (5, 6). Many studies have suggested the contribution of gene variants in relation with the homocysteine metabolism pathway in the susceptibility to obesity, T2DM, or other related traits (7-9).

In T2DM patients, mild hyperhomocysteinemia may promote vascular disease through endothelial injury, predisposing the vessels to atherosclerosis (10). It was reported that high homocysteine levels could be an indicator of a close connection between cardiovascular disease and homocysteine in diabetes mellitus patients (11, 12).

Ultrasonographic determination of common carotid intima-medial wall thickness (cIMT) was used as an early marker for atherosclerosis in previous studies. These studies have demonstrated a close correlation between carotid ultrasound mea-
surement, usually cIMT, and the severity of extracranial carotid atherosclerosis (13, 14). Also, it was noted that cIMT value has been used as a surrogate marker for cardiovascular disease (CVD) in diabetes patients (15). This study was carried out to assess the independent contributions of biochemical and cardiological parameters and the MTHFR C677T genotype to cardiovascular disease in T2DM patients.

**Methods**

**Subjects and identification of diabetes mellitus patients**

A total of 107 T2DM subjects (68 females and 39 males) with severe CVD diagnosed by angiography were included consecutively in this cross-sectional study. The patients received a standard questionnaire, including questions regarding the age at the time of T2DM diagnosis, treatment methods, and other related medical issues. Criteria defined by the American Diabetes Association were used to determine whether a subject was positive for T2DM (16). The study was approved by the local ethics committee, and informed consent from each participant was obtained.

**Inclusion criteria**

In order to determine whether a subject could be included in the study, the following diagnostic criteria were used: symptoms of T2DM plus fasting plasma glucose level ≥126 mg/dL or non-fasting glucose level ≥200 mg/dL, HbA1c value > 6.5%, or ongoing hypoglycemic treatment for at least 1 year. Criteria for CVD were as follows: (1) myocardial infarction (chest pain associated with ECG evidence of myocardial infarction and/or elevated cardiac enzymes) or (2) angiographically proven coronary artery disease (>50% stenosis in 1 or more major epicardial vessels) (3) reported by high systolic (≥140 mm Hg) or diastolic (≥90 mm Hg) blood pressure (17).

**Exclusion criteria**

Individuals who were unable to provide an adequate blood sample were excluded from the study, as were individuals with liver or kidney disease (including diabetic nephropathy), previous organ transplantation, or retinopathy or those who were receiving steroidal therapy at the time of enrollment for this study. Exclusion criteria for the patients included cardiomyopathy, serious organ disease, systemic illness, chronic alcohol abuse, serious psychiatric illness, and anticonvulsant therapy (17).

**Determination of clinical and biochemical parameters**

The clinical and biochemical parameters, as well as cIMT values, were determined using a method described by Aydin et al. (18). Biochemical and cardiological parameters were obtained from venous blood samples of the subjects.

**DNA extraction**

Genomic DNA was isolated from venous blood samples with ethylenediaminetetraacetic acid (EDTA) using phenol-chloroform extraction methods.

**Determination of MTHFR C677T polymorphism**

The MTHFR C677T single-nucleotide polymorphism (SNP) was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using the Hinf I restriction endonuclease enzyme. The DNA segment was amplified from the forward, 5’- TGA AGG AGA AGG TGT CTG CGG GA -3’ and reverse, 5’- AGG ACG GTG CGG TGA GAG TG -3’ primers. The PCR reaction solution contained 2.5 mL dNTPmix (2 mM), 2.5 mL PCR buffer (10x), 1 mL primer pair (10 pmol), 2.5 mL MgCl2 (16 mM), 2.5 mL Taq DNA polymerase (1U), 1 mL genomic DNA (25-100 ng), and 13 mL sterile dH2O. The PCR reaction, based on a method described Kowa et al. (19), yielded 198-bp PCR products. The restriction enzyme reaction was performed using 10x Hinf I buffer R (2 mL), 1 mL Hinf I restriction endonuclease (10 U/mL), 10 mL PCR reaction product, and 7 mL sterile dH2O (total volume of 20 μL). The reaction mixture was incubated at 37°C for 14 hours. The restriction products and genotypes were determined using Hinf I digestion products, yielded by 2.0% agarose gel electrophoresis (Fig. 1).

**Statistical analysis**

Statistical analyses were carried out using the Statistical Package for the Social Science (SPSS) software program, version 15.0, (SPSS Inc. Chicago, IL, USA). Normally distributed continuous variables were analyzed using student t-test and expressed as mean±SD (standard deviation). Abnormally distributed continuous variables were analyzed using Mann-Whitney U test and expressed as median (min-max). Categorical variables were presented as percentages (%) and analyzed using chi-square test. A p<0.05 was considered statistically significant.

**Results**

**Relations between biochemical and cardiological parameters in terms of demographic differences**

Thirty-nine male (63.00±12.30 years of age) and 68 female (61.72±10.35 years of age) patients with T2DM were examined in...
this study. The mean duration of diabetes was 7.09±8.39 years for males and 8.84±8.07 years for females. Body mass index (BMI) was significantly higher (p=0.006) in females (33.53±6.89) than in males (30.25±5.10). While high-density lipoprotein (HDL) cholesterol (p=0.022), total cholesterol (p=0.003), systolic blood pressure (SBP) (p=0.038), folate (p=0.009) and triglyceride (p=0.028) levels were significantly higher in females than males, homocysteine (Hcy) (p=0.015) and visceral fat area (p=0.001) levels were much lower in females than in males. The gender differences were not meaningful for low-density lipoprotein (LDL) cholesterol (p=0.236), fasting plasma glucose (p=0.401), diastolic blood pressure (DBP) (p=0.439), triglyceride (p=0.028), folate (p=0.009) and triglyceride (p=0.028) levels. While the correlation between cIMT and BMI was meaningful (p=0.05), it was not meaningful between cIMT and gender (p=0.330), LDL-cholesterol (p=0.302), HOMO S (p=0.439), triglyceride (p=0.051), SBP (p=0.296), and DBP (p=0.551) values.

In the study population, 31 subjects had the CC genotype (29.0%), 62 had the CT genotype (57.9%), and 14 had the TT genotype (13.1%). The frequencies of T and C alleles were 0.131 and 0.869, respectively (Table 2).

### Table 1. Demographics and clinical parameters of the T2DM patients

| Parameters                  | Male n=39 (36.5%) | Female n=68 (63.5%) | P     |
|-----------------------------|-------------------|---------------------|-------|
| Age, years                  | 63.00±12.30       | 61.72±10.35         | 0.241 |
| Diabetes duration, years    | 3.00 (0.00-30.00) | 7.00 (0.00-35.00)   | 0.036*|
| BMI, kg/m²                  | 30.25±5.10        | 33.53±6.89          | 0.006*|
| cIMT, μm                    | 79.59±21.71       | 76.47±31.64         | 0.552 |
| Total cholesterol, mg/dL    | 170.32±30.62      | 192.89±43.15        | 0.003*|
| HDL-cholesterol, mg/dL      | 38.00 (22.00-66.00) | 43.00 (18.00-107.00)| 0.022*|
| LDL-cholesterol, mg/dL      | 96.50 (57.00-135.00) | 98.00 (55.00-269.00)| 0.236 |
| Triglyceride, mg/dL         | 129.50 (48.00-584.00) | 197.00 (60.00-821.00)| 0.028*|
| Fasting plasma glucose, mg/dL | 125.50 (76.00-450.00) | 135.00 (63.00-377.00)| 0.401 |
| MCV, fL                     | 84.66±4.63        | 82.12±5.20          | 0.013*|
| Serum iron, μg/dL           | 85.50 (23.00-168.00) | 69.00 (19.00-136.00)| 0.021*|
| SBP, mm Hg                  | 142.44±23.34      | 152.01±20.89        | 0.038*|
| DBP, mm Hg                  | 85.38±12.95       | 87.61±13.74         | 0.413 |
| hs-CRP, mg/L                | 1.20 (0.39-53.09) | 1.21 (0.14-68.90)   | 0.833 |
| Folate, ng/mL               | 6.94 (3.50-17.80) | 9.29 (3.73-19.30)   | 0.009*|
| Hcy, μmol/L                 | 12.62±2.58        | 14.83±2.44          | 0.015*|
| Vitamin B12, pg/mL          | 257.00 (150.00-845.00) | 240.00 (151.00-647.00)| 0.418 |
| HgB, g/dL                   | 13.90±1.06        | 12.38±1.57          | 0.000*|
| Hct, %                      | 41.31±2.97        | 37.31±4.33          | 0.000*|
| HbA1c, %                    | 8.0±1.89          | 7.8±2.31            | 0.986 |
| HOMO S, %                   | 2.85 (0.53-8.31)  | 4.28 (0.57-9.25)    | 0.201 |
| Visceral fat area, cm²      | 13.50 (3.00-25.00) | 11.00 (5.00-20.00)  | 0.001*|

### Table 2. MTHFR C677T genotypes and alleles in T2DM patients

| Genotypes | Alleles |
|-----------|---------|
| CC (%)    | C (%)   |
| CT (%)    | T (%)   |
| TT (%)    | N (genotypes) |

C - cytosine; MTHFR - methylene tetrahydrofolate reductase gene; T - thymine; T2DM - type 2 diabetes mellitus; N - number of genotypes

*Values in bold indicate statistical significance (P<0.05). The results are shown as mean±SD (Standard deviation) and median (min-max). BMI - body mass index; cIMT - carotid intima-media thickness; DBP - diastolic blood pressure; Hct - hematocrit; Hcy - homocysteine; HDL - high-density lipoprotein; Hb - hemoglobin; hs-CRP - high-sensitivity C-reactive protein; HOMO S - Homeostasis Model Assessment for Insulin Sensitivity; HbA1c - glycosylated hemoglobin; LDL - low-density lipoprotein; MCV - mean corpuscular volume; N - number of individuals; SBP - systolic blood pressure; T2DM - type 2 diabetes mellitus.

In the study population, 31 subjects had the CC genotype (29.0%), 62 had the CT genotype (57.9%), and 14 had the TT genotype (13.1%). The frequencies of T and C alleles were 0.131 and 0.869, respectively (Table 2).

As far as the MTHFR C677T genotype is concerned, there were no significant differences between subjects with the wild-type allele (677CC) and mutant allele (677CT+677TT) in terms of diabetes duration in years (p=0.384), visceral fat area (p=0.985), and other parameters.
Discussion

In this cross-sectional study, there were no significant differences between subjects with the wild-type allele (677CC) and mutant allele (677CT+677TT) in terms of diabetes duration in years, visceral fat area, total cholesterol, triglyceride, fasting plasma glucose, SBP, DBP, hsCRP, folate, Hcy, vitamin B12, HbA1c, HOMO S, and cIMT values. Sufficient evidence showing an association between MTHFR 677TT and risk of CVD has not been found (4). However, several studies have shown the link between the MTHFR C677T gene polymorphism and coronary risk (20-26). Arai et al. (20) have pointed out the connection between the MTHFR C677T gene polymorphism and myocardial infarction and carotid wall thickening. In a meta-analysis study, no association was found to exist between the C677T polymorphism and the risk of diabetes mellitus in a Chinese population for diabetic nephropathy (DN) or diabetes mellitus (DM) (21), while other studies claimed that the MTHFR C677T polymorphism might influence DN risk but not for DM (22, 23). It was shown that the MTHFR C677T variant was not an independent risk factor for diabetes or CAD in the population of western Iran (24). In other study, the MTHFR T677T genotype was also concluded not to be a risk factor for the development of CVD in T2DM patients (25). However, Morita et al. (26) reported a significantly higher frequency of the MTHFR C677T allele in Japanese CAD patients. They showed that the association was stronger in homozygotes than in heterozygotes and suggested that the MTHFR C677T gene polymorphism may be a risk factor.

Table 3. Clinical and biochemical parameters according to MTHFR C677T genotypes in T2DM patients

| Parameters                          | CC (n=31)                              | CT+TT (n=76)                             | P       |
|-------------------------------------|----------------------------------------|-----------------------------------------|---------|
| cIMT, μm                            | 71.70 (40.00-120.00)                   | 73.30 (40.00-290.00)                    | 0.459   |
| Gender, male/female                 | 12 / 19                                | 27 / 49                                 | 0.756   |
| Age, years                          | 62.56±11.84                            | 61.98±11.47                             | 0.319   |
| Diabetes duration, years            | 2.50 (0.00-35.00)                      | 5.50 (0.00-30.00)                       | 0.384   |
| BMI, kg/m²                          | 32.17±7.96                             | 32.41±5.81                              | 0.882   |
| Total cholesterol, mg/dL            | 183.06±33.56                           | 185.53±43.28                            | 0.778   |
| HDL-cholesterol, mg/dL              | 43.00 (18.00-77.00)                    | 40.50 (22.00-107.00)                    | 0.079   |
| LDL-cholesterol, mg/dL              | 101.00 (57.00-155.60)                  | 96.50 (55.00-269.00)                    | 0.685   |
| Triglyceride, mg/dL                 | 137.00 (48.00-580.00)                  | 182.0 (60.00-821.00)                    | 0.058   |
| Fasting plasma glucose, mg/dL       | 128.00 (76.00-340.00)                  | 131.00 (63.00-450.00)                   | 0.542   |
| Hct, %                              | 38.96±4.18                             | 38.86±4.29                              | 0.108   |
| SBP, mm Hg                          | 148.17±25.34                           | 148.62±21.02                            | 0.931   |
| DBP, mm Hg                          | 86.17±11.94                            | 87.04±14.05                             | 0.749   |
| hsCRP, mg/L                         | 1.28 (0.14-30.60)                      | 1.20 (0.19-68.90)                       | 0.939   |
| Serum iron, μg/dL                   | 77.0 (26.00-168.00)                    | 76.00 (19.00-149.00)                    | 0.635   |
| Folate, ng/mL                       | 8.47 (3.74-19.30)                      | 8.08 (3.50-17.50)                       | 0.668   |
| Hcy, μmol/L                         | 14.48±3.29                             | 14.64±3.06                              | 0.872   |
| Vitamin B12, pg/mL                  | 238.00 (150.00-507.00)                 | 250.50 (151.00-845.00)                  | 0.814   |
| MCV, fl                             | 83.25±5.00                             | 82.96±5.21                              | 0.792   |
| HgB, g/dL                           | 12.99±1.36                             | 12.90±1.68                              | 0.765   |
| Hct, %                              | 38.96±4.18                             | 38.86±4.23                              | 0.977   |
| HbA1C, %                            | 7.80±1.40                              | 8.10±1.50                               | 0.691   |
| HOMO S, %                           | 2.99 (0.59-9.25)                       | 3.67 (0.53-9.17)                        | 0.559   |
| Visceral fat area, cm²               | 12.00 (3.00-25.00)                     | 12.00 (5.00-23.00)                      | 0.985   |

The results are shown as mean±SD (Standard deviation) and median (min-max).

BMI - body mass index; cIMT - carotid intimal-medial thickness; DBP - diastolic blood pressure; Hct - hematocrit; Hcy - homocysteine; HDL - high-density lipoprotein; Hb - hemoglobin; hs-CRP - high-sensitivity C-reactive protein; HOMO S - Homeostasis Model Assessment for Insulin Sensitivity; HbA1c - glycosylated hemoglobin; LDL - low-density lipoprotein; MCV - mean corpuscular volume; N - number of individuals; SBP - systolic blood pressure; T2DM - type 2 diabetes mellitus.
for CAD. Also, the prevalence of stroke is markedly higher in the 677CT and 677TT genotypes compared with the 677CC genotype in T2DM patients (27). The same study suggests that the effect of the MTHFR C677T gene polymorphism on stroke may result from T-allele-linked deleterious effects, C-allele-linked protective mechanisms, or both. In our 107 T2DM patients, the frequencies of the T and C alleles were 0.131 and 0.869, respectively (Table 2). However, we also did not find a significant association between the C677T gene polymorphism and CVD risk in T2DM patients.

Many studies have reported an association between the MTHFR C677T gene polymorphism and clinical parameters, which is related to vascular complications in T2DM patients (10, 28-33). The 677T allele carriers had significantly elevated BMI and higher SBP than 677CC homozygote carriers in peripheral arterial disease in T2DM patients from an isolated aboriginal Canadian population (10). Also, in this study, 677T carriers and noncarriers were not found to have significant differences in age, hypertension, duration of diabetes, DBP and plasma concentrations of fasting blood glucose, HbA1c, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, and C-reactive protein (10). Yilmaz et al. (29) found no correlation between the risk of coronary artery disease (CAD) and MTHFR genotype in Turkish patients. In an elderly Japanese population, a multivariate analysis revealed that this relationship between homocysteine and MTHFR was independent of other risk factors, involving gender, age, history of hypertension, and BMI (p=0.05), there were no meaningful correlations between cIMT values and MTHFR C677T polymorphism, SBP, DBP, LDL and HDL-cholesterol, and triglyceride values.

Consequently, the present study shows that significant differences were not found between subjects with the 677CC allele and 677CT+677TT alleles for cardiac risk factors or for cIMT, hsCRP, and Hcy values in Turkish T2DM patients (Table 3).

Study limitations

Our study has the following limitations. We still could not fully exclude the effect of cardiovascular risk factors in T2DM patients in our results. We did not show lifestyle factors, such as smoking and drinking, and/or the relative basic characteristics of our patients. Another disadvantage was that we had no data on the physical activity and nutrition of the subjects. In order to obtain a clearer picture of the correlation between the MTHFR 677TT gene polymorphism and cardiac risk in T2DM patients, studies should be based on a larger sample size, with the recognition of gene-gene and gene-environment interactions.

Conclusion

We can conclude that the MTHFR 677TT gene polymorphism cannot be used as a marker for assessment of cardiac risk in T2DM patients, because we did not observe any significant differences in terms of the MTHFR C677T polymorphism with cIMT values or the other cardiacological parameters in 107 Turkish T2DM patients without nephropathy and retinopathy. We can say that geographic heterogeneity and lifestyle factors could affect the relationship between MTHFR genotypes and CVD risk in different populations.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept - A.B., R.E., Y.T.; Design - A.B., R.E., Y.T.; Supervision; A.B., R.E., Resource - A.B., R.E., Y.T.; Materials - A.B., Y.T.; Data and/or processing collection - A.B., R.E; Analysis and/or interpretation - A.B., R.E., Y.T.; Literature search - A.B; Writing - A.B.; Critical review - A.B., R.E.; Y.T.

References
1. Audelin MC, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001; 159: 497-511. [CrossRef]
2. Grundy SM, Benjamin U, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-46. [CrossRef]
3. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67. [CrossRef]

polymorphisms in nephropathy-free T2DM patients (49). In our study, while cIMT values depended significantly on age (p<0.001) and BMI (p=0.05), there were no meaningful correlations between cIMT values and MTHFR C677T polymorphism, SBP, DBP, LDL and HDL-cholesterol, and triglyceride values.

We can conclude that the MTHFR 677TT gene polymorphism cannot be used as a marker for assessment of cardiac risk in T2DM patients, because we did not observe any significant differences in terms of the MTHFR C677T polymorphism with cIMT values or the other cardiacological parameters in 107 Turkish T2DM patients without nephropathy and retinopathy. We can say that geographic heterogeneity and lifestyle factors could affect the relationship between MTHFR genotypes and CVD risk in different populations.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept - A.B., R.E., Y.T.; Design - A.B., R.E., Y.T.; Supervision; A.B., R.E., Resource - A.B., R.E., Y.T.; Materials - A.B., Y.T.; Data and/or processing collection - A.B., R.E; Analysis and/or interpretation - A.B., R.E., Y.T.; Literature search - A.B; Writing - A.B.; Critical review - A.B., R.E.; Y.T.

References
1. Audelin MC, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001; 159: 497-511. [CrossRef]
2. Grundy SM, Benjamin U, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-46. [CrossRef]
3. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67. [CrossRef]
4. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201. [CrossRef]
5. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis 2004; 17: 199-205. [CrossRef]
6. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentration. J Nutr 1999; 129: 1656-61.
7. Errera FI, Silva ME, Yeh E, Maranduba CM, Folco B, Takahashi W, et al. Effect of polymorphisms of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian patients. Braz J Med Biol Res 2006; 39: 883-9. [CrossRef]
8. Tavakkoly Bazzaz J, Shojapoor M, Nazem H, Amiri P, Fakhrzadeh H, Errera FI, Silva ME, Yeh E, Maranduba CM, Folco B, Takahashi W, et al. Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to diabetic nephropathy in Chinese type 2 diabetic patients: a meta-analysis. Ren Fail 2013; 35: 1038-43. [CrossRef]
9. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N. Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy or diabetes mellitus in a Chinese population. Clin Invest Med 2010; 33: E290-7. [CrossRef]
33. Rahimi M, Hasanvand A, Rahimi Z, Vaisi-Raygani A, Mozafari H, Rezaei M, et al. Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem 2010; 43: 1333-9. [CrossRef]

34. Kawamoto R, Kohara K, Oka Y, Tomita H, Tabara Y, Miki T. An association of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and ischemic stroke. J Stroke Cerebrovasc Dis 2005; 14: 67-74. [CrossRef]

35. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004; 140: 94-100. [CrossRef]

36. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1203-12. [CrossRef]

37. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000; 23: 1816-22. [CrossRef]

38. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001; 24: 1403-10. [CrossRef]

39. Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Narayan KM, Knowler WC, et al. Impaired glucose tolerance, type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 2000; 43: 156-64. [CrossRef]

40. Bonora E, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M, et al. Impaired glucose tolerance, type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 2000; 43: 156-64. [CrossRef]

41. Bots ML, Dijk JM, Oren A, Grobbee DE. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence. J Hypertens 2002; 20: 2317-25. [CrossRef]

42. Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, Grobbee DE, et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation 2002; 105: 2872-7. [CrossRef]

43. Mazza A, Motti C, Nulli A, Pastore A, Andreotti F, Ammastro V, et al. Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. J Thromb Thrombolysis 1999; 8: 207-12. [CrossRef]

İlaçlar çaresiz, yattık masaya
Yatıp da kalmak var, düştük tasaya
Aslında razıyız, haktan yasaya
Yeter ki olmasın tabip elinden.

Dr. Tahir Akman

Drugs are helpless, I am on the operating table.
I can be boxed on the table, I am worried.
In fact, I consent to everything from the God,
Unless from the surgeon.

Tahir Akman, MD